Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 4/20 | 0.32 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12152032 | 0.91 | CYP2C19 (0.48) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL2629193 | 0.90 | CYP2C19 (0.49) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL2633326 | 0.90 | CYP2C19 (0.49) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL12151985 | 0.88 | CYP3A4 (0.47) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL1733182 | 0.87 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL1733180 | 0.87 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL12151954 | 0.87 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL1733184 | 0.87 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL12151904 | 0.87 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL2628937 | 0.82 | CYP3A4 (0.57) | CYP2C19CYP2D6CYP2C9CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1943221-B1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396830-B2 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| WO-2007041616-A1 | PIPERAZINE AMIDINES AS ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078141-A1 | Piperazine amidines as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078141-A1 | Piperazine amidines as antiviral agents | IDO1, IDO2, EIF2AK2 | CYP2C19 923/4885CYP2D6 455/4885CYP2C9 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.